Project Funding Details

PROJECT SUMMARY The 2022 'Radionuclde Theranostics for the Management of Cancer', a rapidly emerging and important field in cancer diagnosis and therapy, (Theranostics) Gordon Research Conference (GRC) will be held July 17-22, 2022. The scientific goal of this meeting will be to address the challenges of radionuclide theranostics in the field of cancer. This GRC will draw a significant number of attendees (200) and help to develop Radionuclide Theranostics and encourage significant new science in the field. In addition to an expert group of scientists and physicians from academia and private practice, this GRC will also include a large enough number of scientists and clinician specialists from companies developing Radionuclide Theranostics, in order to support a viable conference and continuing community in the future. The specifics of this conference and the planned speakers across basic and translation science will allow this GRC to be of extremely high quality and unique in its approach and will provide enhanced learning opportunities for the advancement of cancer diagnosis and therapy fostering new interactions and collaborations. The unique attributes of the GRC (small, secluded, unpublished data, abundant time for discussion) formats provide an opportunity for formal and informal interactions and collaborations that are likely to have significant and sustained impact on the field. This meeting comes at a pivotal time when precision oncology using radionuclide based imaging and therapy is at a tipping point of innovation and undergoing a fundamental transformation and unprecedented growth to offer more specific and precise antitumoral therapies and diagnostics than ever before. This is evidenced by an ever increasing involvement of large pharmaceutical companies and over 50 new entrants in the field of radiotheranostics and by over 170 active clinical trials using beta, alpha or gamma emitting radionuclides in cancer. The main goal of this GRC is to ensure to attract scientists and clinicians capable of addressing the challenges of radionuclide theranostics in the field of cancer. Funds from this R13 will be specifically targeted to promote participation in the conference by women, under-represented minorities and people with disabilities, particularly graduate students, postdoctoral fellows, and early career investigators and a balance of speakers/discussion leaders.

PROJECT NARRATIVE The 2022 Gordon Research Conference will discuss the latest developments and impact of Radionuclide Theranostics a combined personalized diagnostic and therapeutic tailored to the individual cancer patient down to the cellular level based on their predicted response or risk of disease. This GRC will promote formal and informal interactions and collaborations between speakers and discussants across basic and clinical translational science.